Signalling in prostate cancer

Taxon: Mammal | Human
Process: Cancer
Submitter: Aurelien Naldi

Supporting paper: Montagud, Arnau and Béal, Jonas and Tobalina, Luis and Traynard, Pauline and Subramanian, Vigneshwari and Szalai, Bence and Alföldi, Róbert and Puskás, László and Valencia, Alfonso and Barillot, Emmanuel and Saez-Rodriguez, Julio and Calzone, Laurence (2022). Patient-specific Boolean models of signalling networks guide personalised treatments. eLife. 10.7554/elife.72626

Model file(s)	Description(s)
Montagud2021_Prostate_Cancer.zginml	GINsim file

Summary:
Prostate cancer is the second most occurring cancer in men worldwide, and with the advances made with screening for prostate-specific antigen, it has been prone to early diagnosis and over-treatment. To better understand the mechanisms of tumorigenesis and possible treatment responses, we developed a mathematical model of prostate cancer which considers the major signalling pathways known to be deregulated. The model includes pathways such as androgen receptor, MAPK, Wnt, NFkB, PI3K/AKT, MAPK, mTOR, SHH, the cell cycle, the epithelial-mesenchymal transition (EMT), apoptosis and DNA damage pathways. The final model accounts for 133 nodes and 449 edges. We applied a methodology to personalise this Boolean model to molecular data to reflect the heterogeneity and specific response to perturbations of cancer patients, using TCGA and GDSC datasets.